North America AI-assisted Medical Imaging Market 2025-2032

Report Snapshot

• Trajectory: North America expands to ~US$13.2B by 2032 (~30% CAGR) . (Executive Summary, p.10; Table 1, p.14.)
• Attach rate headroom: OEM AI ships on ~20% of new CT and ~15% of new MR-ample runway across ultrasound and PET. (Attach rate discussion & Figure 3, pp.18-19.)

What's Driving the Numbers

• Reimbursement pull: The U.S. continues to dominate-about 9-to-1 versus Canada-thanks to CMS NTAP renewals (stroke AI) and the emerging CPT stack for CT-FFR, echo strain and breast-AI.
• Enterprise buying power: Large U.S. IDNs lock multi-year "AI-store" licenses, scaling spend faster than underlying scan growth.
• Regulatory clarity: FDA's Predetermined Change-Control Plan draft allows algorithm upgrades without re-filing, shortening refresh cycles and feeding ARR.
• Canada's catch-up: Single-payer provinces move more cautiously, but national lung-cancer screening pilots and CADTH's positive HTA for TB AI push adoption. The lower 29 % CAGR still doubles market size every three years.
• Cross-border vendors: U.S. cloud-AI providers increasingly win Canadian tenders once privacy compliance (PIPEDA/HIPAA) is proven, further narrowing the gap.

Report Benefits

• Where to play / how to win: NA GTM Growth & Maturity Matrix, competitive dataset, regulatory velocity, and M&A watchlist. (Figures & tables, pp.15-18.)
• Country playbooks: U.S. & Canada GTM radars, channel/pricing matrices, customer tier potential, and timelines with 12 month action cues. (U.S. pp.31-38; Canada pp.52-54.)
• Forecast depth: Breakouts by country, modality, clinical area, application, revenue stream, and end use through 2032. (Tables across pp.24-30, 43-51.)

Countries/Regions Covered

• US
• Canada